H. Ni (Munich, Germany)
Author Of 1 Presentation
55P - Molecular Risk Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- EBC
Abstract
Background
Breast cancer ranks first in females, concerning cancer incidence and mortality. Breast cancer in premenopausal patients (vs. postmenopausal patients) has unique gene expression patterns, rendering molecular drivers of tumor progression in premenopausal women of particular clinical interest. Our research focused on premenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (EBC), and the molecular drivers of distant metastases after standard adjuvant treatment.
Methods
We performed a retrospective, single-center, case-control study in premenopausal HR+/HER2- EBC patients treated at the LMU (Ludwig Maximilian University) breast center. We selected 48 patients who developed metastases before 2018 (the median distant metastasis-free survival was 54 months, range: 7-184 months) and 49 patients who did not (the median follow-up was 149 months, range: 121-191 months). All patients received surgery and endocrine therapy, 85.6% received radiotherapy, and 72.2% received chemotherapy. Total RNA of primary tumor FFPE specimens was extracted using the miRNeasy FFPE kit (Qiagen, Germany). Gene expression profiling was done using the NanoString nCounter® system (NanoString technology, USA) with Breast Cancer 360 panel (BC360®) which includes 776 genes across 48 biological signatures, and analyzed following the panel-specific processing protocol (BC360 data analysis).
Results
The bone was the most common site of distant metastases. Tumor size, histological grade, and stage influenced DMFS (distant metastasis-free survival). Claudin-low, mammary stemness, PGR (Progesterone Receptor) signatures were significantly downregulated in patients who developed metastases, and as expected, ROR (Risk of recurrence) was increased. These four signatures were also correlated to patients' DMFS. Besides, ten differentially expressed genes were identified.
Conclusions
Among the tested biological signatures, claudin-low, mammary stemness, PGR, and ROR impact on DMFS in premenopausal patients. Detailed analyses will be presented at the meeting.
Legal entity responsible for the study
The authors.
Funding
The first author receives scholarship from the China Scholarship Council.
Disclosure
H. Ni: Research grant/Funding (self), Scholarship: China Scholarship Council. J. Kumbrink: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: QUIP; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche Pharma. R. Wuerstlein: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Agendia, Onkowissen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Amgen, Paxman; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Aristo, Palleos; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Aristo Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Carl Zeiss, Pierre Fabre; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Celgene, Puma Biotechnology; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Clinsol, Riemser; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Daiichi Sankyo, Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Eisai, Sandoz/Hexal; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Genomic Health; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Glaxo Smith Kline; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Hexal, Seattle Genetics; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Lilly, Tesaro Bio; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Medstrom Medical, Teva; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Mundipharma; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: NanoString; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Odonate. N. Harbeck: Honoraria (self), Advisory/Consultancy: Agendia; Honoraria (self), Advisory/Consultancy: Genomic Health. T.K. Eggersmann: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Aristo Pharma. All other authors have declared no conflicts of interest.
Presenter Of 1 Presentation
55P - Molecular Risk Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- EBC
Abstract
Background
Breast cancer ranks first in females, concerning cancer incidence and mortality. Breast cancer in premenopausal patients (vs. postmenopausal patients) has unique gene expression patterns, rendering molecular drivers of tumor progression in premenopausal women of particular clinical interest. Our research focused on premenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (EBC), and the molecular drivers of distant metastases after standard adjuvant treatment.
Methods
We performed a retrospective, single-center, case-control study in premenopausal HR+/HER2- EBC patients treated at the LMU (Ludwig Maximilian University) breast center. We selected 48 patients who developed metastases before 2018 (the median distant metastasis-free survival was 54 months, range: 7-184 months) and 49 patients who did not (the median follow-up was 149 months, range: 121-191 months). All patients received surgery and endocrine therapy, 85.6% received radiotherapy, and 72.2% received chemotherapy. Total RNA of primary tumor FFPE specimens was extracted using the miRNeasy FFPE kit (Qiagen, Germany). Gene expression profiling was done using the NanoString nCounter® system (NanoString technology, USA) with Breast Cancer 360 panel (BC360®) which includes 776 genes across 48 biological signatures, and analyzed following the panel-specific processing protocol (BC360 data analysis).
Results
The bone was the most common site of distant metastases. Tumor size, histological grade, and stage influenced DMFS (distant metastasis-free survival). Claudin-low, mammary stemness, PGR (Progesterone Receptor) signatures were significantly downregulated in patients who developed metastases, and as expected, ROR (Risk of recurrence) was increased. These four signatures were also correlated to patients' DMFS. Besides, ten differentially expressed genes were identified.
Conclusions
Among the tested biological signatures, claudin-low, mammary stemness, PGR, and ROR impact on DMFS in premenopausal patients. Detailed analyses will be presented at the meeting.
Legal entity responsible for the study
The authors.
Funding
The first author receives scholarship from the China Scholarship Council.
Disclosure
H. Ni: Research grant/Funding (self), Scholarship: China Scholarship Council. J. Kumbrink: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: QUIP; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche Pharma. R. Wuerstlein: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Agendia, Onkowissen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Amgen, Paxman; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Aristo, Palleos; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Aristo Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Carl Zeiss, Pierre Fabre; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Celgene, Puma Biotechnology; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Clinsol, Riemser; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Daiichi Sankyo, Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Eisai, Sandoz/Hexal; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Genomic Health; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Glaxo Smith Kline; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Hexal, Seattle Genetics; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Lilly, Tesaro Bio; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Medstrom Medical, Teva; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Mundipharma; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: NanoString; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Odonate. N. Harbeck: Honoraria (self), Advisory/Consultancy: Agendia; Honoraria (self), Advisory/Consultancy: Genomic Health. T.K. Eggersmann: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Aristo Pharma. All other authors have declared no conflicts of interest.